Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

Rhea-AI Summary

Surmodics, Inc. (SRDX) will release its first quarter fiscal year 2024 financial results on February 1, followed by a conference call and webcast to discuss the results and accomplishments. The live webcast will be accessible through the company's website, while the teleconference can be accessed by dialing a provided number. An audio replay of the conference call will also be available.

Earnings Conference Call and Webcast Will Begin at 7:00 am (CT)

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2024 financial results will be released before the market opens on Thursday, February 1.

Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Thursday, February 1, to discuss the first quarter fiscal 2024 financial results and accomplishments and host a question-and-answer session. To access the webcast, please go to “Events & Presentations” under the “Investors” section of the Company’s website at https://surmodics.gcs-web.com/events-and-presentations, and click on the webcast icon under “Upcoming Events.” To listen to the live teleconference, please dial 877-407-8293 (international callers may dial 201‑689-8349) and provide event ID 13743795.

An audio replay of the conference call will be available beginning at approximately 11 a.m. CT on Thursday, February 1, until approximately 11 a.m. CT on Thursday, February 15, and can be accessed by dialing 877‑660‑6853 (international callers may dial 201-612-7415) and entering access ID 13743795. In addition, the webcast and transcript will be archived on the Company’s website following the call.

About Surmodics, Inc.

Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The Company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116875930/en/

Surmodics Investor Inquiries:

Jack Powell, Investor Relations

ir@surmodics.com

Source: Surmodics, Inc. Surmodics, Inc.

FAQ

When will Surmodics, Inc. release its first quarter fiscal year 2024 financial results?

Surmodics, Inc. will release its first quarter fiscal year 2024 financial results before the market opens on Thursday, February 1.

How can I access the live webcast of the conference call?

The live webcast can be accessed through the 'Events & Presentations' section of Surmodics, Inc.'s website at https://surmodics.gcs-web.com/events-and-presentations.

How can I listen to the live teleconference?

To listen to the live teleconference, please dial 877-407-8293 (international callers may dial 201-689-8349) and provide event ID 13743795.

How long will the audio replay of the conference call be available?

An audio replay of the conference call will be available beginning at approximately 11 a.m. CT on Thursday, February 1, until approximately 11 a.m. CT on Thursday, February 15.

Where will the webcast and transcript be archived?

The webcast and transcript will be archived on Surmodics, Inc.'s website following the call.